Enterprise Therapeutics achieves primary efficacy outcome in Phase 2 clinical trial for cystic fibrosis with novel inhaled ENaC blocker ETD001

Enterprise Therapeutics achieves primary efficacy outcome in Phase 2 clinical trial for cystic fibrosis with novel inhaled ENaC blocker ETD001

Published

News published by Enterprise Therapeutics concerning ETD001, delivered via an investigational eFlow® Technology nebulizer.

 

Read the press release

Back to overview